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Dear friends and colleagues,
In 2002, a small but dedicated group of microbicide researchers and advocates helped form the International Partnership
for Microbicides (IPM) to address what was then an already urgent need — new products women could control to help
them stay free of HIV. Fourteen years later, by forging partnerships with public, private and civil society sectors to develop
microbicides and building on lessons learned in the field, our collective efforts have begun to pay off.
Earlier this year, we announced that two Phase III clinical trials showed IPM’s monthly dapivirine ring can safely help reduce
a woman’s risk of HIV. The road to developing an effective microbicide for women has been a long one — one that could
not have been navigated without the contributions of researchers whose previous work informed the microbicide field;
the inspiring commitment of the women who volunteered for clinical trials, and the communities and advocates who
supported them; the researchers who developed and tested the ring; the pharmaceutical company that donated the
drug; and the donors who invested in the ring’s promise.
The results also offer hope for a new generation of prevention options for women. IPM is advancing its pipeline of
long-acting, self-initiated products, including a 90-day dapivirine ring, a 90-day dapivirine-contraceptive ring that would
simultaneously prevent HIV and unintended pregnancy, and combination products that would leverage the potency of
multiple drugs to prevent HIV.
This is an important moment in HIV prevention and women’s health, but much more needs to be done to achieve
regulatory approval for the dapivirine ring and to deliver it to women. The field also has much to learn about how to best
support women to use HIV prevention methods in general and to ensure new methods meet young women’s needs.
For over a decade, IPM has been guided by the conviction that, one day, women will have multiple HIV prevention options
that work for them — from oral PrEP to rings and the host of other methods now in development. If we seize this moment
to invest in products like the dapivirine ring, we could soon usher in that bright future for women everywhere.

		
Dr. Zeda F. Rosenberg				

Dr. James McIntyre

Although much progress has
been made against HIV/AIDS, the rate
of new infections among women remains
alarmingly high and poses a crisis for
women’s sexual and reproductive health.
According to UNAIDS, the drop in the
number of new adult infections has stalled
and is in danger of reversing — and young
women and girls continue to be at higher
risk. This is especially true in sub-Saharan
Africa, where nearly two of every three new
infections in young people ages 15-24
occur in young women and one in four
pregnancy-related deaths can be linked
to HIV/AIDS.

New developments in HIV prevention
research offer hope that women could soon
have multiple self-initiated options they can
use to protect their own health. Stopping
the virus’s spread will require a range of
prevention options that women can control
themselves, because no single product will
fit into all women’s lives.
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Dapivirine Ring:
A Long-Acting Tool for Women
The dapivirine ring developed by IPM marks a turning

IPM designed the flexible silicone ring to slowly release

HIV prevention product shown to safely help reduce

vagina over the course of a month. Women can insert

point in women’s health: The ring is the first long-acting
infection and is the first microbicide to show
efficacy in two Phase III trials.

an antiretroviral drug (ARV) called dapivirine into the
and replace the ring themselves monthly.

It is a pleasure for me and
my fellow women to have
contributed towards this

important scientific innovation

that could have a lot of potential
to reduce HIV infections among
women like me.

Ring Study participant
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The studies
IPM’s monthly dapivirine ring was evaluated in two Phase III

clinical trials: The Ring Study, conducted by IPM, and ASPIRE,
conducted by IPM’s clinical trial partner, the US National
Institutes of Health-funded
Microbicide Trials

Network (MTN). The

“sister studies” began in
2012 and enrolled over
4,500 participants in

Community outreach
Conducting HIV prevention studies requires extensive

community outreach, involvement and support. IPM worked

with community members in supporting The Ring Study and its

participants through dialogues, small group discussions, events
to encourage male engagement, and informational sessions
and consultations to provide updates, address questions
and build support in preparation for the dapivirine ring
results announcement.

Malawi, South Africa,

Uganda and Zimbabwe.

Left: A soccer game in KwaZulu-Natal
helped engage support for trial participants.
Nearly 25 sporting events were held in Ring
Study trial communities in 2015, reaching
approximately 5,000 community members.

The results
IPM and MTN jointly announced results for both studies in

Below: A community event in
Masiphumelele helped raise
awareness of the ring.

February 2016 at the Conference on Retroviruses and

Opportunistic Infections in Boston. Overall, the monthly ring

reduced the risk of HIV infection among women ages 18-45 by
approximately 30 percent, protecting about one in three
women from infection. Less protection was seen among

Below: Staff from
clinical research centers
participating in The Ring
Study discuss adherence
support strategies and
prepare to share the
dapivirine ring efficacy
results with trial
communities.

women ages 18-21. In ASPIRE, the ring cut HIV risk by more

than half among women over age 21, who were able to use the
product more consistently. Data from both studies strongly

suggest that greater protection can be achieved with more
consistent ring use, or adherence. Additional exploratory

findings from ASPIRE announced in July 2016 suggest the ring
may cut HIV risk significantly with consistent use — by at least
56 percent and potentially higher with near-perfect use. Full
analysis of Ring Study data is forthcoming.
Above: IPM staff at a community
cookout in Limpopo.

I am very happy to be part of this
success — I cannot even hold my
emotions; I feel like crying.

Left: IPM convened its clinical
research partners to maintain
the focus on adherence in The
Ring Study.

Ring Study Community
Advisory Group member
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• Open-label studies

Two “open-label” studies, DREAM and HOPE, began in July

2016 to provide the dapivirine ring to former Ring Study and
ASPIRE participants, respectively, and help show whether
ring use will increase now that the product’s safety and

Next steps for the ring
IPM is collaborating with a network of public,
private, research and civil society partners

at global, national and community levels to
realize the ring’s potential.

efficacy are known. Researchers are encouraged by similar
open-label studies of the daily oral ARV pill Truvada® used

as pre-exposure prophylaxis (PrEP), which showed increases

in adherence and efficacy once participants understood that
the product worked to prevent HIV. Another study to begin
in early 2017 seeks to better understand the prevention

needs of adolescent girls and young women by assessing

their preferences for and adherence to the monthly dapivir-

ine ring or Truvada as daily PrEP. The study will also evaluate
the products’ safety among this young high-risk population
and will examine whether biological factors influence how
the active drugs are taken up in the body. Together, these

studies will also provide insights into adherence challenges
and help identify new approaches to addressing them.
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Left: A lab worker at the Madibeng
Centre for Research in Brits processes a
participant sample for The Ring Study.

•

Applications to regulatory authorities for
the ring’s public use

IPM is assembling a comprehensive dossier of all data

collected on the ring, as required by regulators to apply

for product approval. Data analyses and compilation of the

most recent study results are ongoing, with the first dossier
submissions planned for mid-2017. The earliest potential
product approvals could be received in late 2018.

Data from 14 smaller supporting studies will also be

incorporated into the dapivirine ring regulatory dossier,

including studies to assess ring safety in post-menopausal
women, during menses and with tampon use, and with
male or female condom use, as well as drug-drug
interaction studies.

• Access planning

IPM is working with governments, donors, communities

and other partners across sectors and regions to determine
how the dapivirine ring could best fit into HIV prevention
programs and to accelerate affordable access if it is

approved for public use. Activities include demand-

forecasting and assessments of potential brand names,

as well as the development of a market launch and access
plan that identifies key financing, distribution and

marketing strategies and activities. Initial stakeholder

mapping exercises of four African countries identified
possible manufacturing, distribution, marketing, civil

society and other partners for the ring’s potential rollout.
IPM is also collaborating with implementing partners of
USAID’s Microbicide Product Introduction Initiative to

ensure that the dapivirine ring is integrated into research
and initiatives.

Women have been waiting for this.
The options we currently have are
just too limited.

Divya Bajpai, senior advisor for sexual and
reproductive health and rights, International
HIV/AIDS Alliance

NEW HOPE FOR WOMEN’S HIV PREVENTION
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Building Political and Public Support for Microbicides
From small meetings to a global stage, IPM engages civil

IPM also partnered with civil society organizations to host the

attention on the importance of advancing promising new HIV

Prevention Summit, and organized advocacy events and

society, policymakers and other stakeholders to focus

prevention technologies for women. In 2015, IPM worked

closely with the global advocacy community to ensure that
the UN Sustainable Development Goals (SDGs) included
commitments to ending HIV/AIDS, investing in new HIV

biennial South African National AIDS Council’s Women’s HIV
stakeholder briefings throughout the year across Africa,

Europe, the United States and Canada to provide updates on
the dapivirine ring studies and engage the advocacy

community in advance of dapivirine ring Phase III trial

prevention technologies, and ensuring women’s sexual and

results. IPM, MTN and the advocacy organization AVAC held

IPM-hosted event ahead of the UN Sustainable Development

workers in the four clinical trial countries to share updates and

reproductive health and rights. These efforts culminated in an
Summit in New York that convened global development and
health leaders to discuss the importance of innovation to
achieve the SDGs.

joint consultations with civil society, government and health

request input on the design of the dapivirine ring open-label

studies. This critical advocacy work will continue in 2016 as the
ring moves toward potential regulatory approval and access.

It makes us happy that women
will also have something they
can use to prevent HIV.

Above: A community event at Ndlovu
Medical Centre in Limpopo.

6

IPM 2015 ANNUAL REPORT

Community member at Ring Study
male engagement event

IPM’s Dapivirine Ring: A Product of Partnership
HIV/AIDS is the #1 cause of death among women ages 15-44 worldwide,
and, in sub-Saharan Africa, young women ages 15-24 accounted for one
in four new adult infections in 2015. Women need practical new tools
they can use to protect themselves against HIV.

Partnerships were critical to
the ring’s development:

THE WAY
FORWARD

The dapivirine ring is a testament
to what partnerships can achieve.

The dapivirine ring offers new hope for expanding women’s HIV prevention options.
Only through continued partnership can we realize the ring’s potential.

NEW HOPE FOR WOMEN’S HIV PREVENTION

7

Next-Generation HIV
Prevention for Women

3-month dapivirine-contraceptive ring

IPM is leveraging its ring technology as a platform for new types

mortality that is magnified in women with HIV. Women’s sexual

convenience and different options to meet women’s needs, which

neither should their prevention choices.

new ARVs is also critical to stay ahead of the evolving virus in the

IPM’s 90-day dapivirine-contraceptive ring is designed to slowly

self-initiated products is essential to turning new hope into a

to prevent both HIV and unintended pregnancy. In 2015, IPM

of prevention products that may offer greater efficacy, more

can change throughout their lives. A diverse pipeline that includes

Two of the greatest risks to women’s health are HIV and

unintended pregnancy, a leading contributor to maternal

and reproductive health needs do not exist in isolation, and

long term. Continued investment to develop a diverse pipeline of

release dapivirine and the contraceptive hormone levonorgestrel

new reality.

produced the rings that will be studied in a Phase I trial of the

3-month dapivirine ring

this first-in-human trial will assess the safety as well as the

IPM is developing a ring that could be used for up to three

months at a time, improving its convenience, lowering its yearly

cost and reducing the frequency with which women would visit a

multipurpose product in early 2017. In collaboration with MTN,
pharmacokinetics (how the body processes the drugs) of
the dapivirine-levonorgestrel ring and the three-month
dapivirine-only ring.

health facility to obtain a new ring. This longer-acting dapivirine

DS003 products

contraceptive ring (see next section), results from which will

IPM is pioneering the development of microbicides containing

ring will be studied in the Phase I trial of the dapivirineinform further development of both products.

DS003, a gp120 entry inhibitor licensed from Bristol-Myers Squibb
in 2005 that targets HIV early in its life cycle. In 2015, IPM initiated
the first clinical trial of this novel ARV: a Phase I safety and

tolerability study of a DS003 vaginal tablet. The results of this trial
are expected in late 2016 and will inform the development of a
vaginal ring that combines DS003 with dapivirine.

As long as women continue to be

infected by HIV at high rates, we have
a moral imperative to sustain the

search for prevention options that
women will want and use.

Mitchell Warren, executive director, AVAC
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Rings with multiple ARVs
Combination rings that contain multiple ARVs with different

mechanisms of action may offer greater protection against HIV
and reduce the chance of acquiring drug-resistant virus. IPM

pioneered the first combination microbicide tested in clinical

trials, the dapivirine-maraviroc ring. IPM worked with the Oak

Crest Institute of Science in 2015 to develop new prototypes that
would release higher levels of maraviroc, which IPM acquired in
2008 under a royalty-free license with ViiV Healthcare.

While these prototype rings could inform future combination

ARV product development, findings from IPM’s research on maraviroc suggest that its efficacy as a microbicide may be limited.

IPM, along with its Scientific Advisory Board and Board of Directors, has suspended development of maraviroc, in keeping with
IPM’s prioritization protocol to put resources behind the ARVs

that show the highest likelihood of success as vaginal microbicides. IPM will reassess maraviroc’s potential as a microbicide

when additional data from ongoing clinical trials of maraviroc
are available.

One promising compound now prioritized in IPM’s pipeline
is darunavir, a potent protease inhibitor currently used for

HIV treatment. In 2015, IPM received an exclusive, royalty-free

license for darunavir from Janssen Sciences Ireland UC, one of

the Johnson & Johnson Pharmaceutical Companies. Next steps
include characterization studies to assess the drug’s properties

and prototype development of a darunavir-based combination
ARV ring.

Supporting vaginal and rectal gels
A number of vaginal and rectal gels are being studied by
our clinical trial partners. In 2015, IPM supplied the

clinical materials for a Phase I study of a dapivirine-darunavir
vaginal gel conducted by the European Commission-

By combining our expertise, tools and
passion, we are working to develop

medical solutions that might eventually

help protect generations of women and
girls against HIV.

Wim Parys, vice president, head of R&D for global
public health, Janssen Pharmaceutical Companies
of Johnson & Johnson

funded CHAARM program, and for the University of

Pittsburgh-led CHARM-03, a Phase I study of a maraviroc- based

rectal gel. IPM also collaborated with MTN to design two Phase I
studies of dapivirine rectal gel expected to begin in 2017.
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Strengthening the Body of
Evidence for Women’s HIV
Prevention
IPM contributed to the HIV prevention research base with presentations and publications in major scientific venues in 2015.

Highlights included presenting data from supporting studies of
the dapivirine ring at the 2015 Conference for Retroviruses and
Opportunistic Infections in Seattle and on the dapivirine-

contraceptive ring at the 2015 Controlled Release Society

Annual Meeting in Edinburgh. IPM published work on the multi-

purpose ring and the dapivirine-maraviroc ring and gel in leading

peer-reviewed journals, including the Journal of Acquired Immune
Deficiency Syndromes, Current Opinion in HIV and AIDS, Current

Obstetrics and Gynecology Reports, Pharmaceutical Research and
Advanced Drug Delivery Reviews.

Right: Ring Study
research center
staff at an
adherence
event.
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There was nothing for women which they
can hold in their hands and be

in control of their own destiny.

[The dapivirine ring] is the first time that

something like this is happening … In our
country, HIV is a very feminised disease,
so these are welcome news indeed.
Aaron Motsoaledi, Minister of Health
of South Africa

IPM Donors

Board of Directors

Scientific Advisory Board

2015 Donors

Anova Health Institute, South Africa

Robin Shattock, PhD, Chair
Imperial College London, United Kingdom

Ayo Ajayi, MD, MPH
Bill & Melinda Gates Foundation, Ethiopia

David R. Friend, PhD
Evofem, United States

Pamela W. Barnes, MBA
Independent Consultant, United States

Sharon Hillier, PhD
Magee-Womens Hospital, University of Pittsburgh
School of Medicine, United States

Bill & Melinda Gates Foundation
Flanders Department of Foreign Affairs
Irish Aid, Department of Foreign Affairs
Ministry of Foreign Affairs of Denmark
Ministry of Foreign Affairs of the
Netherlands through the Netherlands
Enterprise Agency
Norwegian Agency for Development
Cooperation, Norwegian Ministry of
Foreign Affairs
United Kingdom Department for
International Development
United States Agency for International Development through the United States President’s
Emergency Plan for AIDS Relief

Previous Donors
Ackerman Family Foundation
Belgian Development Cooperation
Canadian International Development Agency
European Commission
Federal Ministry for Economic
Cooperation and Development, Germany

James McIntyre, MBChB, Chair

Bruce Burlington, MD
Independent Consultant, United States
Georgina Caswell, MA
International HIV/AIDS Alliance, South Africa
Tamar Howson, MS, MBA
Independent Consultant, United States
Florence W. Manguyu, M.Med, MBChB
Aga Khan University Hospital; International AIDS
Vaccine Initiative, Kenya
David Nicholson, PhD
Allergan, United States
Ndola Prata, MD, MSc
University of California, Berkeley School of Public
Health, United States
Zeda F. Rosenberg, ScD
IPM, United States
Michael Stevens
ENTHUSE Charitable Trust, United Kingdom
Heidemarie Wieczorek-Zeul
Former Member of Parliament, German
Bundestag, Germany

Ruth B. Merkatz, PhD, RN, FAAN
Population Council, United States
Thomas Moench, MD
ReProtect, Inc., United States
Derek Newall, PhD
Independent Consultant, United Kingdom
Doug Taylor, PhD
FHI 360, United States
Jim A. Turpin, PhD
National Institute of Allergy and Infectious
Diseases, National Institutes of Health,
United States
Lut Van Damme, PhD, MD
Bill & Melinda Gates Foundation, United States
Jens Van Roey, MD
Janssen Infectious Diseases - Diagnostics BBVA,
Belgium

IPM Leadership
Zeda F. Rosenberg, ScD
Founder and Chief Executive Officer

M•A•C AIDS Fund

Brid Devlin, PhD
Executive Vice President, Product Development

Magee-Womens Research Institute and
Foundation

Kathy Flynn, MBA
Chief Financial Officer

Ministry for Foreign Affairs, Sweden

Mike Goldrich, MBA
President and Chief Operating Officer

Ministry of Foreign Affairs and Cooperation,
Spain
Ministry of Foreign Affairs, France
OPEC Fund for International Development,
the development finance institution of OPEC
Member States

Patricia R. Mayer, PhD
Executive Vice President, Regulatory Affairs
Annalene Nel, MD, PhD
Executive Vice President, Chief Medical Officer,
Clinical Programs

Rockefeller Foundation
Swedish International Development Agency
United Nations Population Fund
World Bank
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2015 Financial Considerations
IPM’s cash, cash equivalents and short-term investments as of

Dec. 31, 2015, totaled $17.8 million. During 2015, IPM continued work in three major activity areas:

• Support to clinical research centers and clinical activities related to The Ring Study, one of two parallel Phase III clinical

IPM’s 2015 financial audits continue a history of full compliance
with all financial reporting requirements from all domestic and

international government and private donors. In 2015, IPM again
received unqualified, or clean, opinions on all audits in both its
South Africa and US offices.

trials of the dapivirine ring in Africa. IPM also spent funds to
support chemistry, manufacturing and control activities in
preparation for a potential application for the ring’s licensure and pre-launch manufacturing requirements.

• Increased regulatory activities to minimize delays in submit-

ting applications for the ring’s licensure once efficacy results

2015 Expenditures by Activity
$33.2M

were known.

4% 4%

• Pipeline products, including funding for the first clinical trial
of DS003, which began in Belgium. Other preclinical work

10%

under way includes development of combination ARV rings

and a dapivirine-contraceptive ring that would prevent both
HIV and unintended pregnancy. This work is conducted

using a highly disciplined approach to product prioritization

38%

11%

that advances only the most promising self-initiated HIV

prevention tools and other sexual and reproductive health
technologies for women, and in consultation with IPM’s

16%

Scientific Advisory Board.

IPM received significant support from donors including the

17%

Ministry of Foreign Affairs of Denmark, the Flanders Depart-

ment of Foreign Affairs, Irish Aid, the Ministry of Foreign Affairs

of the Netherlands, Norad, DFID, USAID and the Bill & Melinda
Gates Foundation. IPM received approximately USD $25.1
million (cash receipts) in 2015.
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Phase III Trial (The Ring Study)
Chemistry, Manufacturing & Controls
Operations & Resource Development
Product Pipeline
Regulatory Preparations for Filing
Access
External Relations

IPM’s Board of Directors, management team and staff are committed

to efficiently and effectively delivering on our mission to advance new
methods to protect women around the world from HIV infection. Sus-

tained donor funding for IPM’s success is essential, and we continue to
advocate for increased funds from existing donors and to pursue new
sources of support to achieve our goals.

2015 Expenditures by Functional Category
$33.2M

		

Assets

Dec. 31, 2015

Cash and cash equivalents

$11,385,029

Investments, at fair value

$6,441,320

Grants receivable

$3,472,484

Prepaid expenses and other assets

$1,479,460

Property and equipment, net
Total Assets

$23,222,913

Liabilities and net assets

2%

3%

Liabilities

9%

Accounts payable and accrued expenses
Accrued payroll liabilities

12%

$444,620

44%

31%

Grant advances and deferred revenue
Deferred rent liability

$4,142,331
$450,583
$5,474,161
$112,229

Total Liabilities

$10,179,304

Net assets
Unrestricted net assets

$13,043,609

Total liabilities and net assets

n
n
n
n
n
n

$23,222,913

External Contracts
Personnel
Consulting Services
Other*
Travel
Depreciation

*Includes rent, internet/phone, clinical trial insurance, legal fees, audit fees, regulatory fees and miscellaneous.
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IPM Headquarters

8401 Colesville Road
Suite 200
Silver Spring, MD 20910 USA
Tel: +1-301-608-2221
Fax: +1-301-608-2241

IPM South Africa

63 Main Road
Paarl 7646, South Africa
P.O. Box 3460
Tel: +27-21-860-2300
Fax: +27-21-860-3208/1000

Learn more about how to promote women’s health worldwide
and save millions of lives at www.IPMglobal.org
Follow us on Twitter at @IPMicrobicides

